Masato Ozaka

Masato Ozaka

Auto-generated profile, based on publicly available information

Masato Ozaka

Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2018 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
MOMasato Ozaka
Masato Ozaka
HIHiroshi Ishii
Hiroshi Ishii
TSTosiya Sato
Tosiya Sato
MUMakoto Ueno
Makoto Ueno
MIMasafumi Ikeda
Masafumi Ikeda
JFJunji Furuse
Junji Furuse

27 December 2022 in European Journal of Cancer
Verified
Journal Article
Open access
MOMasato Ozaka
Masato Ozaka
KNKohei Nakachi
Kohei Nakachi
SKSatoshi Kobayashi
Satoshi Kobayashi
AOAkihiro Ohba
Akihiro Ohba
HIHiroshi Imaoka
Hiroshi Imaoka
JFJunji Furuse
Junji Furuse
We compared the efficacy of modified 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) with that of gemcitabine plus nab-paclitaxel (GnP) for locally advanced pancreatic cancer (LAPC). Patients with untreated LAPC were randomly assigned (1:1) to receive mFOLFIRINOX or GnP. One-year overall survival (OS) was the primary endpoint. The major secondary end-points included progression-free survival (PFS), response rate (RR), carbohydrate antigen 19-9 (CA19-9) response, and adverse events. The sample size was 124 patients to select a more effective regimen with a minimum probability of 0.85 and to examine the null hypothesis of the 1-year OS <53%. Of the 126 patients enrolled from 29 institutions, 125 were deemed eligible. The 1-year OS was 77.4% (95% CI, 64.9-86.0) and 82.5% (95% CI, 70.7-89.9) in the mFOLFIRINOX and GnP arms, respectively. The median PFS was 11.2 (95% CI, 9.9-15.9) and 9.4 months (95% CI, 7.4-12.8) in the mFOLFIRINOX and GnP arms, respectively. The RR and CA19-9 response rate were 30.9% (95% CI, 19.1-44.8) and 57.1% (95% CI, 41.0-72.3) and 42.1% (95% CI 29.1-55.9) and 85.0% (95% CI, 70.2-94.3) in the mFOLFIRINOX and GnP arms, respectively. Grade 3-4 diarrhoea and anorexia were predominant in the mFOLFIRINOX arm. GnP was considered the candidate for a subsequent phase III trial because of its better RR, CA19-9 response, and mild gastrointestinal toxicities. Both regimens displayed higher efficacy in the 1-year survival than in the historical data of gemcitabine monotherapy.

17 January 2012 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
MOMasato Ozaka
Masato Ozaka
YMYuji Matsumura
Yuji Matsumura
HIHiroshi Ishii
Hiroshi Ishii
YOYasushi Omuro
Yasushi Omuro
TITakao Itoi
Takao Itoi
TNToshifusa Nakajima
Toshifusa Nakajima

31 March 2021 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
TTTsuyoshi Takeda
Tsuyoshi Takeda
TSTakashi Sasaki
Takashi Sasaki
CSChisaki Suzumori
Chisaki Suzumori
TMTakafumi Mie
Takafumi Mie
TFTakaaki Furukawa
Takaaki Furukawa
NSNaoki Sasahira
Naoki Sasahira

7 September 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MNMasahiro Nakatochi
Masahiro Nakatochi
YLYingsong Lin
Yingsong Lin
HIHidemi Ito
Hidemi Ito
KHKazuo Hara
Kazuo Hara
FKFumie Kinoshita
Fumie Kinoshita
Keitaro MatsuoKeitaro Matsuo
Keitaro Matsuo
Genome-wide association studies (GWASs) have identified many single nucleotide polymorphisms (SNPs) that are significantly associated with pancreatic cancer susceptibility. We sought to replicate the associations of 61 GWAS-identified SNPs at 42 loci with pancreatic cancer in Japanese and to develop a risk model for the identification of individuals at high risk for pancreatic cancer development in the general Japanese population. The model was based on data including directly determined or imputed SNP genotypes for 664 pancreatic cancer case and 664 age- and sex-matched control subjects. Stepwise logistic regression uncovered five GWAS-identified SNPs at five loci that also showed significant associations in our case-control cohort. These five SNPs were included in the risk model and also applied to calculation of the polygenic risk score (PRS). The area under the curve determined with the leave-one-out cross-validation method was 0.63 (95% confidence interval, 0.60–0.66) or 0.61 (0.58–0.64) for versions of the model that did or did not include cigarette smoking and family history of pancreatic cancer in addition to the five SNPs, respectively. Individuals in the lowest and highest quintiles for the PRS had odds ratios of 0.62 (0.42–0.91) and 1.98 (1.42–2.76), respectively, for pancreatic cancer development compared with those in the middle quintile. We have thus developed a risk model for pancreatic cancer that showed moderately good discriminatory ability with regard to differentiation of pancreatic cancer patients from control individuals. Our findings suggest the potential utility of a risk model that incorporates replicated GWAS-identified SNPs and established demographic or environmental factors for the identification of individuals at increased risk for pancreatic cancer development.

Verified
Journal Article
Open access
PDF file
TSTakashi Sasaki
Takashi Sasaki
TTTsuyoshi Takeda
Tsuyoshi Takeda
TOTakeshi Okamoto
Takeshi Okamoto
MOMasato Ozaka
Masato Ozaka
NSNaoki Sasahira
Naoki Sasahira
Biliary tract cancer refers to a group of malignancies including cholangiocarcinoma, gallbladder cancer, and ampullary cancer. While surgical resection is considered the only curative treatment, postoperative recurrence can sometimes occur. Adjuvant chemotherapy is used to prolong prognosis in some cases. Many unresectable cases are also treated with chemotherapy. Therefore, systemic chemotherapy is widely introduced for the treatment of biliary tract cancer. Evidence on chemotherapy for biliary tract cancer is recently on the increase. Combination chemotherapy with gemcitabine and cisplatin is currently the standard of care for first-line chemotherapy in advanced cases. Recently, FOLFOX also demonstrated efficacy as a second-line treatment. In addition, efficacies of isocitrate dehydrogenase inhibitors and fibroblast growth factor receptor inhibitors have been shown. In the adjuvant setting, capecitabine monotherapy has become the standard of care in Western countries. In addition to conventional cytotoxic agents, molecular-targeted agents and immunotherapy have been evaluated in multiple clinical trials. Genetic testing is used to check for genetic alterations and molecular-targeted agents and immunotherapy are introduced based on tumor characteristics. In this article, we review the latest evidence of chemotherapy for biliary tract cancer.